melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, subungual/interdigital melanomas had a significantly higher frequency of copy number aberrations (67%) than other subgroups (P = 0.02), particularly in CDK4 and cyclin D1, and were less likely to have BRAF mutations or a superficial spreading histologic subtype (P = 0.05) compared with volar acral melanomas.
|
28870692 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-365 Inhibits Cell Growth and Promotes Apoptosis in Melanoma by Targeting BCL2 and Cyclin D1 (CCND1).
|
29858490 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, we observed a significant increase in p21 and Cyclin D1 in the TAN skin of un-irradiated trigenic RXRα <sup>ep-/-</sup> mice, suggesting that those changes might be consequences of loss of functional RXRα in the melanoma microenvironment.
|
29121869 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The primary outcome was the difference in p16 and cyclin D1 staining between benign blue nevi and malignant melanoma.
|
26766120 |
2017 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Neither cell distribution in cell cycle and CCND1 expression nor activity of signaling pathways crucial for melanoma development and maintenance, including the RAF/MEK/ERK pathway, WNT/β-catenin pathway and NF-κB signaling, were affected by the presence of different growth factors.
|
28829835 |
2017 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of cyclin D1 and N-cadherin promote melanoma proliferation and invasion.
|
29344161 |
2017 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Melanoma tumors from control group showed reduced proliferation, down-regulated expression of cyclin D1 and increased expression of cyclin-dependent kinase inhibitor p16, suggesting dermal fibroblasts blocked the onset of melanoma tumor formation by inducing a cell cycle arrest in B16F10 melanoma cells.
|
27061029 |
2016 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dysregulation of the p16-cyclin D1-CDK4/6-Rb pathway occurs frequently in melanoma; however, the therapeutic efficacy of CDK4/6 inhibition remains to be critically evaluated.
|
26988987 |
2016 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have observed that the p16Ink4a, AMACR, cyclin D1, and E-cadherin showed no exclusive staining for nevi or melanomas.
|
25149154 |
2014 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
At the molecular level, we show that melanoma Rh123(low) cells overexpress HIF1α, pluripotency factor OCT4, and the ABCB5 marker of melanoma stem cells and downregulate the expression of Cyclin D1 and CDK4.
|
23355370 |
2013 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Positive results were obtained in 72% of melanomas via the four-probe FISH assay (RREB1/MYB/CEP6/CCND1).
|
23800576 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, we have seen associations between IRF4, PARP1, and CCND1 and phenotypic characteristics, confirming previous results for the IRF4 gene and presenting novel data for the last two, suggesting that pigmentation characteristics correlated with eye color are potential mediators between PARP1 and MM protection.
|
23537197 |
2013 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the latter case, the melanocytoma exhibited an immunophenotype that featured nuclear p27 and no HMB45 staining, with very low Cyclin D1 expression compared with the melanoma that featured little nuclear but more cytoplasmic p27 positivity, much higher Cyclin D1 expression and HMB45 positivity.
|
23685997 |
2013 |
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively analyzed 17 cases and focused on the histologic presentation and the expression of c-Kit, epidermal growth factor receptor (EGFR), cyclin D1/Bcl-1, PS100, and HMB45 and searched for BRAF, NRAS, and KIT mutations that are known to be associated with melanoma subtypes, together with amplifications of KIT, cyclin D1, cyclin-dependent kinase 4, MDM2, and microphthalmia-associated transcription factor using quantitative polymerase chain reaction.
|
23664541 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This case is the first such description in the lung, and it is characterized with a battery of immunohistochemical stains; BRAF mutation status was negative, and fluorescence in situ hybridization analysis revealed increased copy number gains in 11q (cyclin D1), which is associated with poor prognosis in melanoma.
|
23278726 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
It has been recently demonstrated that the LSI RREB1(6p25)/LSI MYB(6q23)/LSI CCND1(11q13)/CEP6 fluorescence in-situ hybridization (FISH) assay is a reliable tool with which to distinguish benign naevi and melanomas.
|
22211292 |
2012 |
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A number of genes previously recognized to have an important role in the development and progression of melanoma were identified including homozygous deletions of CDKN2A (13 of 39 samples), CDKN2B (10 of 39), PTEN (3 of 39), PTPRD (3 of 39), TP53 (1 of 39), and amplifications of CCND1 (2 of 39), MITF (2 of 39), MDM2 (1 of 39), and NRAS (1 of 39).
|
22250051 |
2012 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Explorations revealed that expression of cyclin D1 and pAKT was increased in newly developed primary melanomas compared with nevi (P = .01 and P = .03, respectively).
|
22614973 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously showed that a 4-probe FISH assay targeting 6p25 (RREB1), 6q23 (MYB), Cep6 (centromere 6), and 11q13 (CCND1) could discriminate between histologically unequivocal melanomas and benign nevi with a sensitivity of 86.7% and specificity of 95.4%.
|
22588064 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we report 7 cases of melanoma with HSR for cyclin D1.
|
22456513 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data show that CCND1 amplification could have a prognostic relevance in cutaneous melanoma and highlight that altered CCND1 gene expression may influence the metastatic progression, survival, and the localization of metastases.
|
23001925 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using a four-probe fluorescence in situ hybridization (FISH) assay targeting RREB1, MYB, Cep6, and CCND1, we found that seven of the eight propositus cases showed chromosomal aberrations consistent with the standardized FISH diagnostic criteria for melanoma.
|
22892832 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ROC1 expression is negatively correlated with cyclin D1 expression, demonstrating its importance in the degradation of cyclin D1 in melanomas.
|
21300445 |
2011 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated a fluorescence in situ hybridization (FISH) assay, which has previously been shown to be of value for the diagnosis of melanocytic nevi and melanomas of the skin, using probes targeting 6p25 (RREB1), 6q23 (MYB), 11q13 (CCND1) and centromere 6 (CEP6), for its potential to assist in the distinction of conjunctival melanocytic nevi from melanomas.
|
20100177 |
2010 |
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Amplifications of the cyclin D1 gene are detected in normal-looking 'field melanocytes', which represent a latent progression phase of acral melanoma that precedes the stage of atypical melanocyte proliferation in the epidermis.
|
19788535 |
2010 |